The deal is bid to strengthen Amgen's drug portfolio as it prepares to face several patent expirations for key treatments over the next decade.
Representatives for Horizon Therapeutics and Amgen did not immediately respond to a request for comment from CNBC. The FTC declined to comment.for information about the acquisition as part of the agency's review of the deal.to buy Horizon Therapeutics in early December and said it expected to complete the sale in the first half of this year.for key treatments over the next decade., an autoimmune condition that causes inflammation of the skin.
Horizon, which is based in Ireland, would beef up Amgen's drug offerings with treatments for rare, autoimmune and severe inflammatory diseases. Horizon carries two fast-growing drugs, including the thyroid eye disease treatment Tepezza and the gout medicine Krystexxa.about the deal's potential impact on competition in the drug market.
The acquisition and another proposed merger in the biopharma industry — between Indivor and Opiant — could "cause further price increases on lifesaving drugs and prevent affordable alternatives from entering the market," WarrenShe called on the FTC to "heavily scrutinize" the two deals.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
FTC to block Amgen's $27.8 billion deal for Horizon Therapeutics - sourceThe U.S. Federal Trade Commission is expected to file a lawsuit as early as Tuesday to block Amgen Inc's $27.8 billion deal to buy Horizon Therapeutics PLC , a person familiar with the matter told Reuters.
Leer más »
Horizon shares sink on report that FTC will sue to block takeover by AmgenShares of Horizon Therapeutics Inc. plunged 15% in extended trading Monday after Bloomberg News reported the FTC is expected to file a lawsuit to block Amgen...
Leer más »
Ray Therapeutics Tackles a Rare Blinding Disease With $100 Million in FinancingGene therapies may help a wider group of patients with retinitis pigmentosa, a vision disorder that leads to blindness. Ray Therapeutics is looking to treat people who’ve lost their sight, while other startups are aiming at earlier stages.
Leer más »
Robocall company behind 'billions' of illegal calls sued by FTCXCast Labs, a company accused of helping make billions of illegal robocalls, was sued on Friday by the U.S. Federal Trade Commission, which asked the court to order the company to stop the practice.
Leer más »
'Mars Horizon 2' game is getting a real scientist to help with realismThe team behind the highly anticipated 'Mars Horizon 2' game has recruited a real planetary scientist to ensure the game is as realistic as reasonably practicable.
Leer más »
Deadline to Claim Your Share of AT&T Slow Data Speed Settlement Nears: What to KnowTime is running out to claim your share of AT&T’s $60 million “data-throttling” settlement. Those eligible have until Thursday, May 18, to file a claim. AT&T already refunded $52 million to current and former customers, but couldn’t reach all those owed, according to the Federal Trade Commission (FTC). The FTC is now tasked with disseminating the remaining $7 million or…
Leer más »